Aim: Spinal cord injury (SCI) causes increased apoptosis of neurons, leading to irreversible dysfunction of the spinal cord. In this study, we investigated the effects of the progression of SCI and potential regulation of apoptosis after the Pleckstrin homology (PH) domain and leucine rich repeat protein phosphatase 1 (PHLPP1) gene was silenced. Main methods: Spinal cord injection, and neuronal transfection with a recombinant adenovirus vector encoding small interfering RNA (siRNA) against PHLPP1 (AdsiPHLPP1) successfully silenced PHLPP1. These created in vivo and in vitro PHLPP1-silenced models, respectively, resulting in stable expression of the transgene in neurons. Key findings: The results showed that silencing of PHLPP1 evidently reduced levels of the nuclear factor erythroid 2-related factor 2 (Nrf2) after SCI. Western blot analysis revealed that the mice injected with AdsiPHLPP1 showed increased the expression of pro-apoptotic factors (Bax and cleaved-caspase 3), and reduced levels of neurotrophic (BDNF) and anti-apoptotic (Bcl-2) factors, both in vivo and in vitro. The motor function of AdsiPHLPP1-injected mice was restored more slowly than that of wild type (WT) mice. In addition, the number of motor neurons surviving in the anterior horn of the spinal cord was also reduced after SCI. Significance: Our results confirm that silencing of PHLPP1 promotes neuronal apoptosis and inhibits functional recovery after injury in vivo and in vitro. Consequently, PHLPP1 represents a potential therapeutic target gene for the clinical treatment of SCI.
Introduction
Spinal cord injury (SCI) is one of the most difficult conditions to diagnose. It can lead to severe dysfunction of the lower limbs, high levels of disability, and mortality. It commonly includes both primary injury and secondary injury. Primary injury is caused by external trauma acting directly on the spinal cord, thereby causing irreversible repair. Secondary injury is the result of a series of biochemical reactions caused by a primary injury, including oxidative stress, an inflammatory response, or an increase in neuronal apoptosis [1] [2] [3] . Currently there is no effective clinical treatment for primary injury of the spinal cord. Furthermore, we know very little about the molecular mechanisms underlying secondary injury. However, the development of techniques that could reduce the number and extent of biochemical reactions that occur in secondary injury would represent a very useful step forward in the treatment of SCI.
The Pleckstrin homology (PH) domain and leucine rich repeat protein phosphatase (PHLPP) belongs to the family of Ser/Thr protein phosphatases and consists of an N-terminal portion of the PH domain structure, a leucine-rich repeat (LRR) structure domain, a PP2C phosphatase domain, and a C-terminal PDZ ligand [4, 5] . There are two known sub-types, PHLPP1 and PHLPP2, expressed in hippocampal neurons [6, 7] . Furthermore, PHLPP1 can promote the apoptosis of tumor cells [8, 9] and inhibit the invasive ability of tumor cells, thus suppressing tumorigenesis. A recent report shows that the expression of PHLPP1 is increased in a model of myocardial ischemia-reperfusion injury [10] . In contrast, selectively inhibited PHLPP1 in primary hippocampal neurons reportedly increases the levels of pro-apoptotic factors levels [11] . Therefore, PHLPP1 may play different roles in different cells.
Protein kinase B (AKT) survival signaling provides a major substrate for PHLPP1. High levels of PHLPP1 leads to the dephosphorylate of pAkt473, which promotes apoptosis [12, 13] . Reduced expression of PHLPP1 is highly correlated with a shorter survival in patients with pancreatic ductal adenocarcinoma (PDAC), because a reduction in PHLPP1 levels leads to pAkt473 activation, and mediates the development of PDAC [14] . Furthermore, in vitro reports on cardiomyocytes show that knockdown of pAkt473 inhibits Nuclear factor erythroid 2-related factor 2 (Nrf2) nuclear translocation and induces apoptosis [15] . As a transcription factor, Nrf2 binds to the Kelch-like ECH-associated protein (Keap1) in the cytoplasm in an inactive state [16] . When tissue has been injured, Nrf2 is released from the cytoplasm to the nucleus to assume an active state, simultaneously activates downstream target heme oxygenase-1 (HO-1) [17, 18] , and has a protective effect on damaged neuronal cells [19] . As far as we know, pAkt473/Nrf2 can regulate apoptosis in diseased states, but the regulatory mechanisms associated with the action of PHLPP1 on pAkt473/Nrf2 in the spinal cord remains unclear.
Therefore, in this study, we used AdsiPHLPP1 to silence PHLPP1, and thereby create PHLPP1-silenced models in vivo and in vitro. We then investigated the effects of PHLPP1 silencing and its role in the regulation of pAkt473/Nrf2 and neuronal apoptosis after SCI. Our findings maybe provide evidence of the potential of PHLPP1 as a therapeutic target gene for effective treatment following SCI.
Materials and methods

Animals and the establishment of an animal model for SCI
Adult female mice (weight: 18-23 g; age: 6-7 weeks) were purchased from, and fed in the specific pathogen-free Experiment Animal Center of Jinzhou Medical University. All experimental procedures were approved by the Ethics Committee of Jinzhou Medical University (Permit Number: SCXK (Liao) 2014-0004). A total of 60 adult mice were randomly assigned to four groups, five mice per group within three repeated experiments. The four groups were treated as follows: Sham (T9-10 laminectomy only); SCI; PHLPP1 silencing (spinal cord injection AdsiPHLPP1 for 3 days); and PHLPP1 silencing + SCI. Wild type (WT) mice were those that had not been injected with AdsiPHLPP1. A mouse model of SCI was established using Allen's method [20] . Mice were anesthetized by an injection of 10% chloral hydrate (3.0 mL/kg, i.p.). The skin and muscles were then incised along the midline, in order to perform a laminectomy at the T9-10 level. A 1 mm diameter, 3 g impactor was then dropped from a height of 50 mm onto the surface of the spinal cord at T9-10, leading to a spinal cord contusion injury. The muscles and skin were then sutured in layers. Bladders were manually expressed twice a day until normal function was recovered.
Cell culture
A six-well plate was pretreated with poly-D-lysine (Sigma-Aldrich, USA) one night before seeding. Pregnant mice were euthanized and a cesarean section was performed 13-15 days into pregnancy. The spinal cords of fetal mice were removed, minced well, and digested in papain (Solarbio, China). Cells were maintained in high-glucose Dulbecco's modified Eagle's medium (DMEM) (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) (Sera Pro, Germany) and 0.5% penicillin/ streptomycin (Gibco, USA) for 8 h. The culture medium was then changed to a neurobasal medium (Gibco) composed of 2% B27 (Gibco), 0.25% GlutaMAX (Gibco), and 0.5% penicillin/streptomycin (Gibco, USA), and maintained in an incubator at 37°C, with 5% CO 2 for 7-10 days. The purity of cultured neurons was determined by immunofluorescence. Cells were treated in groups, based on the treatment groups of the mice. 
. Production of recombinant adenovirus
We used the AdMax™ system to generate the recombinant adenovirus as follows: three small interfering RNAs (siRNAs) bearing different PHLPP1 cDNAs and an adenoviral vector bearing green fluorescent protein (GFP) were cotransfected into human embryonic kidney 293 (HEK293) cells. Recombinant adenovirus (AdsiPHLPP1) was obtained via the action of the Cre/loxP recombinase system. After AdsiPHLPP1 was transfected into HEK293 cells, viral plaques were allowed to develop for 15 days, after which the viral supernatant was collected. Crude viral lysates were used for plaque purification. The virus was propagated in HEK293 cells, purified by cesium chloride density gradient centrifugation, and stored at −80°C. The resultant titer of AdsiPHLPP1 was 1 × 10 12 infectious units/mL (IFU/ml).
Animals
Laminectomy at the level of T9-10 was carried out on mice, as described above. A 30-gauge needle was then fitted to a Hamilton syringe and used to inject 10 μL AdsiPHLPP1 or AdsiGFP (designed by Sangon Biotech, China) at rate of 2 μL per min into the exposed area of the spinal cord. After injection, the needle was slowly withdrawn and the wound was sutured, as described above. After three days, mice were euthanized and the spinal cord was resected for western blot analysis, to determine whether the AdsiPHLPP1 injection had the desired silencing effect [21] . Thus, an animal model of gene silencing was established, which had been created for study of the SCI model, as described above. All in vivo transduction studies used a viral vector titer of 6.0 × 10 11 IFU/mL. The sequences of AdsiPHLPP1 were as follows:
AdsiPHLPP1-1: F: ccggcgcagccctgtctgtaaataactcgagttatttacagacagggctgcgttttttg, R: aattcaaaaaacgcagccctgtctgtaaataactcgagttatttacagacagggctgcg. AdsiPHLPP1-2: F: ccggggctgtctcattcgattctatctcgagagaatcgaatgagacagccaattttttg, R: aattcaaaaaattggctgtctcattcgattctctcgagatagaatcgaatgagacagcc. AdsiPHLPP1-3: F: ccgggctgagtgaaatcacgttaccctcgagtaacgtgatttcactcagctcttttttg, R: aattcaaaaaagagctgagtgaaatcacgttactcgagggtaacgtgatttcactcaga.
Primary neurons
Primary neuronal culture was carried out as described above. On day 7, cells were transfected with AdsiPHLPP1 in serum-free medium diluted to a multiplicity of infection (MOI) of 40 for 8 h [22] [23] [24] . Fresh medium was then added and cells were left to incubate for an additional 3 days [25] . Cells were collected for protein analysis or observation of the effects of transfection under a fluorescence microscope. The MTT (5 mg/mL) (Sigma-Aldrich, USA) solution was prepared in phosphate buffer saline (PBS), filtered, and added to each well, after which the plates were incubated for 4 h at 37°C. Subsequently, purple formazan crystals were dissolved in 150 μL of dimethyl sulfoxide (DMSO). The absorbance was then measured at a wavelength of 470 nm. Data were calculated as the proportion of surviving cells using the following formula:
Cell viability assay
where A t and A c are the absorbance of the treatment and control groups, respectively.
Immunofluorescence
Sections of the spinal cord injected with AdsiPHLPP1 were dried at room temperature (RT) for 30 min, and then washed three times for 5 min each with 1 × PBS. Primary neurons were fixed with 4% paraformaldehyde at RT for 30 min and 0.1% Triton-X-100 for 10 min at RT, and then washed three times for 5 min each with 1 × PBS. Treated sections and cells were then blocked with normal goat serum (ZSGBBio, China) at 4°C for 2 h. The sections were then incubated overnight at 4°C with the following primary antibodies: anti-GFAP (1:1000, ab4674, Abcam, UK) and anti-NeuN (1:1000, ab104224, Abcam). The cells were incubated with anti-NeuN (1:1000, ab104224, Abcam) overnight at 4°C. The following morning, sections and cells were then washed three times for 5 min each with 1 × PBS and incubated with Alexa Fluor™ 568 (1:500, Life Technologies, USA) for 2 h at RT. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) for 15 min and images were captured with a fluorescence microscope (Leica, Germany).
Nissl staining
Frozen spinal cord sections (20 μm) from within 0.5 cm of the point of injury were prepared, warmed for 30 min at RT, and washed twice in triple-distilled water for 2 min. Sections were then incubated for 5 min at 37°C with Nissl staining solution (Beyotime, China), and then washed twice for a few seconds. Sections were further dehydrated with 95% ethanol for 10 min, and then treated with xylene for 10 min before being mounted with neutral gum. The number of surviving neurons in three sections of the anterior horn of the spinal cord from each mouse was then calculated by raters who were blinded to the experimental groups, and these values were used for further analysis.
Western blot
Tissue and cell samples were first homogenized in radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime, China). Protein samples (40 μg) were then separated by 10% SDS-PAGE and transferred to 0.22 μm polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 5% skimmed milk and dissolved in Trisbuffered saline with Tween-20 (TBST) for 2 h at RT. They were then incubated overnight at 4°C with the following primary antibodies against anti-PHLPP1 (1:1000, ab71972, Abcam); anti-Bax (1:1000, ab32503, Abcam); anti-Bcl-2 (1:1000, ab136285, Abcam); anti-cleavedcaspase 3 (1:1000, 9664s, Cell Signaling Technology, USA), anti-BDNF (1:1000, NBP1-46750, Novus Biologicals, USA); anti-Nrf2 (1:1000, ab31163, Abcam); anti-HO-1 (1:1000, ab13248, Abcam); anti-pAkt473 (1:2000, 4060s, Cell Signaling Technology); anti-pAkt308 (1:1000, 13038s, Cell Signaling Technology); anti-Akt (1:1000, 4685s, Cell Signaling Technology); and GAPDH (1:1000, ab9484, Abcam). The membranes were then incubated with an appropriate secondary antibody, goat anti-mouse or anti-rabbit IgG-HRP (1:10,000, Earthox, USA, mouse: E030110-01; or rabbit: E030130-01) at RT for 2 h. Immunoreactive bands were developed using a ChemiDoc-It™TS2 Imager (UVP, USA) and analyzed using the ImageJ2× software. All experiments were repeated three times.
Behavioral assessment
Hind limb motor function was evaluated on days 1, 5, 7, 14, 21 and 28 following SCI in an open-field using locomotor rating on the Basso mouse scale (BMS) [26] was employed by three independent evaluators, who were double-blinded to the assessment. Mice from each group (n = 5) were observed for 4 min in each session and hind limb motor performance was evaluated using a 9-point scale. Mean scores were calculated for all subsequent analyses.
Statistical analysis
All data were presented as means ± standard error of the mean (SEM). The unpaired Student's t-test was used to compare means from the two treatment groups. Multi-group comparisons were performed using one-way analysis of variance (ANOVA) followed by the Turkey's post hoc test, or two-way ANOVA followed by the Bonferroni post hoc test. The Mann-Whitney U test was used for the analysis of BMS scores. Statistical analyses were carried out and the half-maximal inhibitory concentration (IC50) was determined using the SPSS 19.0 software.
Results
Mice in which PHLPP1 was silenced showed delayed motor function recovery after SCI
To evaluate the effect of PHLPP1 silencing (AdsiPHLPP1-3) on functional recovery of the hind limbs after SCI, we used the BMS to assess hind limb locomotor performance of both wild type (WT) and PHLPP1-silenced mice within 28 days of SCI. All of the injured mice were completely paralyzed after the first day of injury, and motor function of the hind limbs was gradually recovered with time. However, BMS scores for the WT group were higher than those for the AdsiPHLPP1-3 group. The BMS scores showed that at the beginning of the seventh day, the recovery of hind limb function in the AdsiPHLPP1-3 SCI group (BMS score: 0.8 ± 0.2) was significantly lower than that in the WT SCI group (BMS score: 1.8 ± 0.38), (P < 0.05). On the 28th day, the BMS score of the WT SCI group was 5.2 ± 0.38, compared to 3.4 ± 0.25 in the AdsiPHLPP1-3 SCI group (P < 0.001) (Fig. 1) . These results showed that the lack of PHLPP1 had adverse effects upon the recovery of hind limb function in mice.
Silencing of PHLPP1 reduces the number of surviving motor neurons after SCI
To evaluate the effect of PHLPP1-silencing (AdsiPHLPP1-3) on the morphology of the spinal cord tissue, we counted the number of surviving motor neurons in the anterior horn of the spinal cord using Nissl staining. In both groups, as time elapsed, the number of motor neurons was gradually reduced. On each day of evaluation, the AdsiPHLPP1-3 group had significantly fewer motor neurons than the WT group, showing the most significant differences on days 1 and 7 (P < 0.001) (Fig. 2) . These data suggest that silencing of PHLPP1 can reduce the number of surviving motor neurons in the anterior horn of the spinal cord after SCI in mice. Fig. 1 . Mice in which PHLPP1 was silenced showed delayed motor function recovery after SCI. The BMS scores of wild type (WT) and AdsiPHLPP1-3 mice were evaluated on days 1, 5, 7, 14, 21, and 28 after SCI. Data represented mean ± SEM (n = 5).
⁎ P < 0.05, ⁎⁎⁎ P < 0.001, compared to AdsiPHLPP1-3 mice.
Adenovirus-mediated genes were effectively expressed in the spinal cord and primary neurons
To investigate the transfection efficiency of the adenovirus-mediated gene, we used an adenovirus carrying GFP that was injected into the spinal cord of mice. The pattern of GFP fluorescence was assessed after three days and observed to be localized to the gray matter of the anterior horn of the spinal cord (Fig. 3A) .
The neuronal marker, NeuN, was used to stain the spinal cord of mice injected with AdsiGFP. We found that the areas of GFP infection were consistent with the location of neurons (Fig. 3B ). In addition, during spinal cord staining, GFAP was used as a marker of transduced GFP-positive astrocytes; however, no such astrocytes were observed (Fig. 3C) . Three adenovirus vectors encoding siRNAs against PHLPP1 (AdsiPHLPP1-1, 2, and 3) and the control (AdsiGFP) were transfected into the spinal cord. The results of western blot analysis showed that the silencing efficiency of AdsiPHLPP1-1, 2, and 3, in comparison to AdsiGFP, was 35.8%, 46.5%, and 82.5%, respectively. Based on these results, AdsiPHLPP1-3 was the most effective (P < 0.001) (Fig. 3F) , and was therefore used in further experiments.
Primary neurons were stained with NeuN on the seventh day of culture, and the purity of neurons was observed using immunofluorescence (Fig. 3D) . Primary neurons were transfected with AdsiGFP for 8 h, after which fresh medium was added, and the culture was maintained for 3 days. Green fluorescence was observed directly under a fluorescence microscope and GFP was observed to be colocalized in the neurons (Fig. 3E) . Collectively, these results show that AdsiPHLPP1-3 was effectively transfected into the neurons, both in vivo and in vitro.
Silencing of PHLPP1 reduces Nrf2 expression after injury
To investigate that the relationship between PHLPP1 silencing (AdsiPHLPP1-3) and pAkt473/Nrf2 after injury, we evaluated the expression of pAkt473, Nrf2, and its downstream protein HO-1, at three different time points. In Fig. 4A , the expression level of pAkt308 in the AdsiPHLPP1-3 group is lower than that in the WT group on each day, however this difference was not significant. In addition, only the expression of pAkt473 in the AdsiPHLPP1-3 group was higher than in the WT group on the seventh day after injury; however, this difference was not statistically significant. After injury, the expression of Nrf2 gradually increased with time in the WT group, and the opposite was true for the AdsiPHLPP1-3 group in vivo. The expression level of Nrf2 in the AdsiPHLPP1 group was significantly lower than that in the WT group on day 7 (P < 0.001). However, HO-1 was significantly lower in the AdsiPHLPP1-3 group than in the WT group on day 1 (P < 0.001), but showed no significant differences on days 5 and 7 (Fig. 4B) . In vitro, we first determined the effects of H 2 O 2 on cell viability by the MTT assay. Cultured neurons were treated with H 2 O 2 at a concentration of 200 μmol/L for 24 h to establish the injury model (Fig. 4C) . Western blot analysis confirmed the silencing effect and showed that the expression of PHLPP1 was significantly reduced (P < 0.001). We also noted that the expression of PHLPP1 (P < 0.05), Nrf2 (P < 0.001), and HO-1 (P < 0.01) in H 2 O 2 -treated cells that had been transfected was significantly lower than that in cells that had not transfected (Fig. 4D) . Collectively, these data showed that the silencing of PHLPP1 could reduce the expression of Nrf2 after injury, both in vivo and in vitro.
Silencing of PHLPP1 reduces the levels of neurotrophic factors after injury
In vivo, the expression of neurotrophic factors was detected by western blot analysis on days 1, 5 and 7 after SCI. After injury, the expression of brain-derived neurotrophic factor (BDNF) in the AdsiPHLPP1-3 group showed a gradual reduction with time, and was lower than that in the WT group on day 7 (P < 0.001) (Fig. 5A) . In vitro, the expression of BDNF in H 2 O 2 -treated cells that had been transfected was significantly lower than that of in non-transfected cells (P < 0.001) (Fig. 5B) . These results suggest that silencing of PHLPP1 reduces the production of neurotrophic factors after injury, both in vivo and in vitro. 
Silencing of PHLPP1 promotes neuronal apoptosis after injury
To investigate the effects of PHLPP1-silencing (AdsiPHLPP1-3) on apoptosis, we quantified pro-apoptotic and anti-apoptotic factors by western blot analysis in vivo and in vitro. In vivo, as time elapsed, the expression of Bcl-2 showed a gradual decline in both groups, but was remarkably reduced in the AdsiPHLPP1-3 group compared to the WT group after SCI; however, this difference was only significant on days 5 and 7 (P < 0.05). The expression of Bax and cleaved-caspase 3 in the AdsiPHLPP1-3 group was significantly higher than that in the WT group; this difference was particularly notable on day 7 (P < 0.001) (Fig. 6A) . In vitro, the expression of Bcl-2 in H 2 O 2 -treated cells that were transfected was lower than that in non-transfected cells (P < 0.05), whereas the expression of Bax was significantly increased in transfected cells (P < 0.001) (Fig. 6B) . These results revealed that silencing of PHLPP1 significantly promotes neuronal apoptosis after injury. (AdsiGFP, AdsiPHLPP1-1, 2, and 3) for 3 days, and collected for western blot analysis (relative levels were normalized to GAPDH expression, n = 3).
⁎⁎ P < 0.01, ⁎⁎⁎ P < 0.001, compared to the WT group.
Discussion
In this study, we found that the potential target gene, PHLPP1, plays an important role in SCI through its influence on neuronal apoptosis. First, we used AdsiPHLPP1-3 silenced PHLPP1 to create PHLPP1-silenced models. We observed that the silencing of PHLPP1 could successfully reduce the expression of Nrf2, but not pAkt473 after injury, both in vivo and in vitro. Second, silencing of PHLPP1 also reduced the number of surviving motor neurons and neurotrophic factors, and promoted neuronal apoptosis, thereby delaying functional recovery of the hind limbs after SCI.
Although the local injection of AdsiPHLPP1-3 into the spinal cord can have a silencing effect, the effect of the adenovirus itself on the spinal cord remains unclear. Previous research has shown that the effects of injecting of lentiviral vectors encoding GFP or Nrf2 into the mouse hippocampus can be expressed at the injection site; whereas the histological cytotoxicity of neurons remains negligible. Moreover, an adenovirus vector encoding BDNF, which was injected into adult rats, was able to be expressed efficiently [21, 27] . In the present study, primary neurons were transfected with AdsiPHLPP1-3 for 8 h [23, 24] . Fresh medium was then added and cells were incubated for an additional 3 days [25] in vitro. The AdsiPHLPP1-3 was injected into the spinal cord of mice for 3 days in vivo to create PHLPP1-silenced models. Immunofluorescence results showed that the expression of AdsiGFP was localized in the neurons. Western blot analysis showed that the expression of PHLPP1 was reduced, suggesting the successful creation of PHLPP1-silenced models, both in vivo and in vitro. In a previous experiment, we detected the PHLPP1 levels within 7 days of SCI in control mice. The expression of PHLPP1 was the lowest on the first day, close to normal levels on the fifth day, and the highest on the seventh day (results not shown); therefore, we chose these three days for follow-up experiments.
Studies have shown that PHLPP1 directly phosphorylates pAkt473, but not pAkt308 [6, 12] . Deletion of PHLPP1 enhances Akt activation in the neuron, and can significantly increase cell viability and reduce infarct size after cerebral artery occlusion [28] . However, the present study (Fig. 4A) shows that the expression of pAkt308 declined with increasing time post-injury, even though this difference was not statistically significant. The expression of pAkt473 showed a gradual increase with increasing time post-injury, and this expression in the AdsiPHLPP1-3 group was higher than that in the WT group on the seventh day; however, this difference was also not statistically significant. These results are not consistent with those of previous reports. Furthermore, selective inhibition of PHLPP1 activity in hippocampal neurons reportedly reduces the expression of pAkt473 and increases the levels of pro-apoptotic factors [11] . Furthermore, pAkt473 levels in the cortex have been recently reported to show no increase 7 days after a traumatic brain injury in PHLPP1 KO mice vs. WT mice. The histological outcome was also adverse in PHLPP1 KO mice vs. WT mice 24 h after a traumatic brain injury [29] . The above results may imply that PHLPP1 regulates pAkt473 differently in different tissues, more studies are needed to elucidate the signaling mechanisms involved in PHLPP1-mediated neuroprotection in the spinal cord.
Previous studies have demonstrated that Nrf2 in cells of the central nervous system has a neuroprotective effect, and that the upregulation of Nrf2 can protect neurons after injury [30] . Our study showed that Nrf2 expression gradually increased with increasing the time post-injury in the WT group, implying that Nrf2 triggers neuroprotection after injury. However, in the AdsiPHLPP1-3 group, the expression of Nrf2 was at a high level even before injury. These levels gradually declined with increasing time post-injury, and became lower than that in the WT group on day 5; however, this difference was most significantly on day 7 (Fig. 4B) . Altogether, silencing of PHLPP1 can inhibit neuroprotective effects through reduced Nrf2 expression after SCI. The expression of HO-1 in the AdsiPHLPP1-3 group was lower than that in the WT group on day 1 alone. This means that the expression of HO-1 in mice injected (mean ± SEM, n = 3, respectively).
⁎ P < 0.05; ⁎⁎ P < 0.01,
with AdsiPHLPP1-3 was not mediated by Nrf2. The expression levels of Nrf2 and HO-1 in neurons transfected with AdsiPHLPP1 and treated with H 2 O 2 were lower than those of untransfected neurons (Fig. 4D) . Collectively, these data showed that silencing of PHLPP1 reduces the Nrf2 expression after injury. Earlier reports have shown that BDNF can promote the regeneration of neurons after SCI [31, 32] . Furthermore, new neurons can be induced when exogenous BDNF is injected into the adult rat brain [33] . Increased expression of BDNF can be promoted by Nrf2 [34] . In our experiments, the mice injected with AdsiPHLPP1-3 expressed relatively high levels of BDNF before SCI. Treatment of hippocampal neurons with BDNF reportedly results in reduced levels of PHLPP1 [35] . This finding partially supports the present results. However, the expression of BDNF after injury in vivo was remarkably lower in AdsiPHLPP1-3 group than in the WT group, especially on the seventh day. The changes observed in Nrf2 and BDNF expression are consistent with those reported in a previous study [34] . Moreover, the expression of BDNF in AdsiPHLPP1-3 cells was also significantly reduced after injury. These results suggest that PHLPP1 silencing can cause a reduction in the levels of neurotrophic factors, thereby delaying the recovery of motor function after SCI.
Neuronal apoptosis can increase secondary injury in the spinal cord by influencing various regulatory pathways [36] [37] [38] . Following SCI, members of the Bcl-2 family control cell death and activate members of the caspase family during process of apoptosis [39] . The B-cell lymphoma 2 (Bcl-2) family and Bcl-2 associated X protein (Bax) both play roles in the inhibition and promotion of apoptosis [40] [41] [42] . Caspase 3 is normally inactive, but is cleaved by the initiator caspase after SCI to exert a pro-apoptotic effect; levels of cleaved-caspase 3 are useful indicators of the extent of apoptosis [43, 44] . In the present study, the expression of anti-apoptotic Bcl-2 was reduced after infliction of the injury. The AdsiPHLPP1-3 group showed a greater decline in this factor than the WT group. In contrast, the expression of pro-apoptotic Bax and cleaved-caspase 3 were significantly increased, and the AdsiPHLPP1 group showed a greater increase than the WT group, especially on the seventh day after injury, both in vivo and in vitro. The number of motor neurons in the AdsiPHLPP1-3 group was also significantly reduced after injury, as evidenced by Nissl staining. Moreover, the BMS scores of mice in the AdsiPHLPP1-3 group were significantly lower than those in the WT group after SCI. Collectively, these data indicate that silencing of PHLPP1 causes the acceleration of neuronal apoptosis, thereby delaying the functional recovery. However, this study focused only on the role of PHLPP1 silencing in the recovery of motor function after SCI in mice, and did not detect the expression of PHLPP1 following SCI in humans. Therefore, the next step in our research will be to analyze the expression of PHLPP1 in clinical samples of different grades of SCI, which will provide further evidence for any potential role of PHLPP1 in the clinical treatment of SCI.
In conclusion, our study demonstrated that silencing of PHLPP1 could reduce the expression of Nrf2 in neurons, promote neuronal apoptosis, and delay motor function recovery after SCI in mice. These findings may provide evidence for the potential of PHLPP1 as a therapeutic target gene for the clinical treatment of SCI.
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